ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Denosumab

Also written as “denosumab”, “CT-P41” and “AMG 162”.

Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Breast Neoplasms · Giant Cell Tumor of Bone · Prostatic Neoplasms, led by 13 companies.

Drug pageDenosumab: every studyMany companies study it; this page follows only the 78 they lead. All 207 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 20, 201278 company-led studies, 5 open or runningNext primary completion: Jan 23, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only553 open or runningphase 4since Nov 20, 2012Aug 6, 2002Jan 23, 2027phase 4 · NCT06332014
GlaxoSmithKlineits history only50 open or runningphase 3since Oct 20, 2011Oct 20, 2011none ahead
Celltrionits history only30 open or runningphase 3since Feb 12, 2021Aug 11, 2020none ahead
Mabwell (Shanghai) Bioscienceits history only30 open or runningphase 3since Jan 18, 2022Mar 12, 2021none ahead
Daiichi Sankyoits history only20 open or runningphase 3since May 16, 2008May 16, 2008none ahead
Fosun Pharmaits history only20 open or runningphase 3since Apr 23, 2022Aug 27, 2020none ahead
Shanghai Biomabs Pharmaceuticalits history only20 open or runningphase 3since Oct 15, 2020Apr 18, 2019none ahead
AryoGen Pharmedits history only10 open or runningphase 3since Sep 19, 2017Sep 19, 2017none ahead
Hamad Medicalits history only10 open or runningphase 3since Jan 22, 2017Jan 22, 2017none ahead
Lambda Therapeutic Researchits history only11 open or runningphase 3since Jun 7, 2022Jun 7, 2022none ahead
Taizhou Mabtech Pharmaceutical10 open or runningphase 1since Apr 7, 2024Apr 7, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Taizhou Mabtech Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 7, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06361355 · 128 enrolled · China

TargetBeta

TNFSF11 →read by rule
“A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity”NCIt, by rule
“Tumor necrosis factor ligand superfamily member 11 inhibitor”ChEMBL 37, by rule

Other programs on TNFSF11

ProgramCompanyFurthest phaseStudies
QL1206ruleQilu Pharmaceuticalphase 35
SHR-2017Jiangsu HengRui Medicinephase 12

Studies

The one study Taizhou Mabtech Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06361355Healthy Volunteers · China1CompletedJun 3, 2024128

How it is read

Names in the registry

  • “Denosumab”, 41 entries
  • “denosumab”, 10 entries
  • “CT-P41”, 3 entries
  • “AMG 162”, 3 entries
  • “Prolia®”, 2 entries

Codes read as this program: CMAB807.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.